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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. TANK binding kinase 1 (TBK1) regulates the interferon regulatory
factor (IRF) 3 and IRF7 activation pathways by double strand RNA
(dsRNA) via Toll like receptor (TLR) 3 and by lipopolysaccharide
(LPS) via TLR4. Rebamipide is useful for treating inflammatory
bowel disease (IBD). Although IBD is associated with nuclear factor 
κB (NF κB), any association with the TBK1 IRF pathway remains
unknown. How rebamipide affects the TBK1 IRF pathway is also
unclear. We analyzed the relationship between IBD (particularly
ulcerative colitis; UC) and the TLR TBK1 IRF3/7 pathway using
human colon tissue, a murine model of colitis and human colonic
epithelial cells. Inflamed colonic mucosa over expressed TKB1,
NAP1, IRF3, and IRF7 mRNA compared with normal mucosa. TBK1
was mainly expressed in inflammatory epithelial cells of UC
patients. The expression of TBK1,  IRF3,  IRF7,  IFN α and IFN β
mRNA was suppressed in mice given oral dextran sulfate sodium
(DSS) and daily rectal rebamipide compared with mice given only
DSS. Rebamipide reduced the expression of TBK1, IRF3 and IRF7
mRNA induced by LPS/dsRNA, but not of NF κB mRNA in colonic
epithelial cells. Rebamipide might suppress the TLR TBK1 pathway,
resulting in IRF3/7 induction of IFN α/β and inflammatory factors.
TBK1 is important in the induction of inflammation in patients
with UC. If rebamipide represses the TLR TBK1 pathway, then rectal
administration should suppress inflammation of the colonic mucosa
in patients with UC.
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Introduction The pathogenesis of inflammatory bowel disease (IBD) remains
unclear. The immune response to viral or bacterial infection
is thought to be one etiology of intestinal inflammation. Toll-like
receptors (TLR) induce innate immune responses by recognizing
invading microbial pathogens that cause the activation of adaptive
immune responses.(1,2) In TLRs, TLR3 and TLR4 impart ligand-
specific recognition of double-stranded RNA (dsRNA) of viruses
and of bacterial lipopolysaccharide (LPS), respectively.(3,4) The
LPS- or polyinosine:polycytidine (poly(I:C))-induced activation
of the Toll/IL-1R domain-containing adaptor inducing interferon
(IFN)-β (TRIF; TICAM-1), which is an adaptor that functions
independently of MyD88, leads to the delayed activation of
nuclear factor-κB (NF-κB).(5,6) TRIF also induces activation of the
transcriptional regulator, IFN regulatory factor (IRF) 3, and the
expression of IFN-β and of IFN-inducible genes through the
activation of TANK-binding kinase 1 (TBK1) and inhibitor of
kappaB kinase ε (IKKε).(7,8) TLR3 activates primarily the TRIF
pathway, whereas TLR4 activates both MyD88- and TRIF-
dependent pathways—Both IKKε(9,10) and TBK1(11–13) are key
regulators of the IRF3 and IRF7 activation pathways in cells that
have been exposed to viruses and/or activated by dsRNA via
TLR3.(7,14) NF-κB is induced by poly(I:C)/LPS through TLR3/
4,(15) and NF-κB activation is required for the release of proinflam-
matory cytokines, including interleukin-1 (IL-1), interleukin-6
(IL-6), and tumor necrosis factor (TNF).(16)
The initiation and perpetuation of the inflammatory intestinal
responses in IBD might result from an exaggerated host defense
reaction of the intestinal epithelium to endogenous luminal
bacterial flora and viruses via TLR3/4-signaling. TLR3 is signifi-
cantly down-regulated in intestinal epithelial cells from patients
with active Crohn’s disease (CD) but not in those with ulcerative
colitis (UC). In contrast, TLR4 is obviously up-regulated in both
UC and CD.(17) Moreover, a relationship has been identified
between IBD and NF-κB,(18) but not between IBD and the TBK1-
IRF pathway.
Rebamipide is widely used in Japan to treat gastric ulcers(19)
and gastric injury.(20) Recently, there was a report of administered
rebamipide enemas to a patient with IBD complicated by proc-
titis.(21) The therapeutic efficacy of rebamipide has been indepen-
dently confirmed by others using a model of colitis induced by
acetic acid(22) or dextran sulfate-sodium (DSS).(23,24) However,
the relationship between rebamipide and TBK1 has not been
described.
Here, we analyzed the relationship between IBD (in particular,
UC) and the TLR-TBK1-IRF3/7 pathway. We then evaluated the
effect of rebamipide on the TBK1-IRF3/7-IFN-α/β pathway and
on the NF-κB activation pathway using colonic epithelial cells and
mice with colitis induced by DSS.
Material and Methods
Human samples and tissue collection. Biopsy specimens
of normal and moderately or severely inflammatory mucosa
obtained during colonoscopy of 10 patients with UC at Nagoya
City University Hospital between 2005 and 2007 were stored at
−80°C for mRNA detection.
The Ethics Committee of Nagoya City University Graduate
School of Medical Sciences granted approval for this study and
written informed consent was obtained from all patients to
participate in all procedures associated with the study.
Immunohistochemistry of UC patients. Immunohisto-
chemical staining of colon tissues was performed with antibodies
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against TBK1 (EP611Y, abcam, Tokyo, Japan; dilution 1:50). The
procedure was performed with the appropriate positive and nega-
tive controls. Briefly, 3-μm-thick sections were deparaffinized
and hydrated through a graded series of alcohols. After inhibition
of endogenous peroxidase activity by immersion in 3% H2O2/
methanol solution, antigen retrieval was achieved by heating the
samples in 10 mM citrate buffer (pH 6.0) using a microwave
oven for 10 min at 98°C. Then, sections were incubated with the
primary antibody. After thorough washing in PBS, the samples
were incubated with biotinylated the secondary antibody and then
with avidin-biotin horseradish peroxidase complexes (Vectastain
Elite ABC kit, Vector Laboratories, Inc., Burlingame, CA).
Finally, immune complexes were visualized by incubation with
0.01% H2O2 and 0.05% 3,3'-diaminobenzidine tetrachloride (DAB).
Experimental procedures of DSS mice. Eight-week-old
female C57BL/6 mice were housed under conventional conditions
in a temperature-controlled room with a 12 h light/dark cycle.
Colitis was induced in the mice by orally administering 3%
dextran sulfate sodium (DSS; MP Biomedicals Inc., Morgan, CA)
in distilled water daily for 5 days. The mice were assigned to
groups as follows: Control (no DSS and no rebamipide), DSS
(oral DSS alone), DSS + rebamipide (oral DSS plus daily rectal
administration of 50 mg/kg/day of rebamipide dissolved in 100 μl
of 0.5% carboxymethylcellulose (CMC; Wako Pure Chemical
Industries Ltd., Osaka, Japan). All mice were sacrificed 5 days
after DSS administration was started. The Animal Care Committee
of Nagoya City University approved the study protocol.
Histopathology of DDS mice colon tissues. All specimens
were routinely processed and stained with hematoxylin and eosin
for histological examination.
Cell culture. Human colonic cancer cells (CaCo2; ATCC
number, HTB-37) were seeded in 6-cm dishes at a density of
2 × 106/dish and cultured for 48 h with RPMI1640 (Sigma
Chemical Co., St. Louis, MO) supplemented with 10% fetal calf
serum, 1% ampicillin and streptomycin in 5% CO2.
Reagents. Lipopolysaccharide (LPS) from Escherichia coli
O55:B5 and poly(I:C) were purchased from Sigma Chemical
Co. and Amersham Biosciences (Pittsburgh, PA), respectively.
Rebamipide was provided by Otsuka Pharmaceutical Co. Ltd.
(Tokyo, Japan).
Experimental procedures of human colonic epithelial
cells. Sub-confluent CaCo2 cells were incubated with Poly(I:C)
or LPS at 37°C for 24 h to examine the TLR3 and TLR4 signaling
pathways, respectively, in the presence or absence of rebamipide.
Thereafter mRNA and protein expression were examined in the
cells as described below.
Real time RT PCR. Total RNA was isolated from CaCo2 cells
using TRIzol (Invitrogen, Carlsbad, CA). First-strand cDNA
was synthesized using Superscript II (Invitrogen) according to
the manufacturer’s instructions. Primers for human TLR3, TLR4
and control human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were obtained from Applied Biosystems (CA; TLR3,
Hs00152933 m1; TLR4, Hs01061963 m1; GAPDH, 4310884E).
The primers for human TBK1, NAP1, IRF3, IRF7, NF-κB and
control human acid ribosomal phosphoproteins (ARP) are listed in
Table 1 and those for mouse TBK1, IRF3, IRF7, IFN-α, IFN-β
and control mouse β-actin are listed in Table 2. Real-time RT-PCR
for TLR3 and TLR4 proceeded using an ABI 7500 Fast Real-Time
PCR system (Applied Biosystems). Real-time RT-PCR proceeded
in a 20-μl volume containing 18 μl of TaqMan Fast Universal PCR
Master Mix (Applied Biosystems), 1 μl cDNA and 1 μl primers.
Reactions for TBK1, NAP1, IRF3, IRF7, IFN-α, IFN-β, control
human  ARP and control mouse β-actin proceeded in a 20-μl
volume containing 18 μl of Power SYBR Green PCR Master Mix
(Applied Biosystems), 1 μl cDNA and 20 μM primers. Uniform
amplification of the products was reconfirmed by analyzing the
melting curves of the amplified products. All reactions proceeded
in triplicate to assess reproducibility.
Western blotting. CaCo2 cells were washed with PBS (−)
and subsequently dissolved in 1× lysis buffer (Cell Signaling
Technology) containing 20 mmol/l Tris-HCl (pH 7.5), 150 mmol/l
NaCl, 1 mmol/l Na2EDTA, 1 mmol/l EGTA, 1% Triton, 2.5 mmol/l
sodium pyrophosphate, 1 mmol/l β-glycerophosphate, 1 mmol/l
Na3VO4, and 1 μg/ml leupeptin. Cells were disrupted using a
Bio-ruptor sonicator (Cosmo Bio, Tokyo, Japan) for 15 s, and
then lysates were centrifuged at 15,000 rpm for 10 min at 4°C. All
samples were normalized to an equal protein concentration using
a protein assay kit (Bio-Rad Laboratories, CA). An equal quantity
of 2× SDS-PAGE sample buffer (0.5 mol/l Tris-HCl (pH 7.2), 1%
SDS, 100 mmol/l β-mercaptoethanol, and 0.01% bromophenol
blue) was added to the samples, and then the mixtures were boiled
for 5 min at 100°C. Portions of boiled samples were fractioned on
7.5%, 10% or 12.5% SDS-PAGE gels and then transferred to
nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala,
Sweden). Non-specific binding on the membranes was blocked
with 5% skimmed milk in PBS (−) for 1 h at room temperature.
The membranes were incubated with TBK1 monoclonal antibody
(clone: 108A429, Gene Tex, Inc., Irvine, CA) overnight at 4°C
Table 1. Human primer sets
Upper primer Lower primer
IRF3 tcttccagcagaccatctcc tgcctcacgtagctcatcac
IRF7 cagatccagtcccaaccaag gtctctactgcccacccgta
TBK1 agcggcagagttaggtgaaa ccagtgatccacctggagat
NAP1 tgggaggtggaaaagttgag ccgtttgtttggctttctgt
NF κB tctgcttccaggtgacagtg atcttgagctcggcagtgtt
ARP cgaagccacgctgctgaacatgctcaac gctgccattgtcgaacacctgctggatg
Table 2. Mouse primer sets
Upper primer Lower primer
TBK1 gagagctggaggacgatgag acggtagccccgtacttctt
IRF3 gatggagaggtccacaagga gagtgtagcgtggggagtgt
IRF7 cctcttgcttcaggttctgc gctgcatagggttcctcgta
IFN α agtgagctgacccagcagat agacagccttgcaggtcatt
IFN β ccctatggagatgacggaga acccagtgctggagaaattg
β Actin gatctggcaccacaccttct ggggtgttgaaggtctcaaadoi: 10.3164/jcbn.10 69
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followed by three washes with 0.05% Tween 20 in PBS (−) at 5-
min intervals. The membranes were incubated with an appropriate
secondary antibody for 1 h at room temperature, followed by three
washes with 0.05% Tween 20 in PBS (−) at 5-min intervals.
Immunoreactive proteins were visualized using the ECL Plus
Western blotting Detection system (Amersham Biosciences).
Filters were stripped and reprobed using monoclonal β-actin
antibody (Abcam Plc., Cambridge, England) as an internal control.
Immunofluorescence microscopy. CaCo2 cells in a sub-
confluent state were incubated with Poly(I:C) or LPS at 37°C
for 24 h respectively, in the presence or absence of rebamipide.
Thereafter TBK1 was analyzed by immunofluorescence study.
Cells were fixed with ethanol and acetone. Incubation with
primary antibody of TBK1 was performed in a solution of PBS
containing 0.1% milk at room temperature. Then, sections were
incubated with the appropriate secondary antibody and all sections
were counterstained with 4',6-diamidino-2-phenylindole (DAPI)
(Kirkegaard and Perry Laboratories). Images were obtained with
an Eclipse 80i fluorescence microscope (Nikon, Tokyo, Japan).
Results
Inflammatory mucosa of UC over expressed TBK1 IRF3/7
signaling pathway. We first performed real-time RT-PCR of
TBK1, NAP1, IRF3, and IRF7 to confirm the relationship between
the mRNA expression of these genes and UC in 10 patients. The
mRNA expression of all these genes was higher in atypical, than
in normal mucosa from the patients (Fig. 1). These results indi-
cated that the inflammation associated with UC is related to the
TBK1-IRF3/7 signaling pathway.
Immunohistochemical analysis of TBK1 in UC. We per-
formed immunohistochemical staining of TBK1 in UC tissues
from humans. TBK1 was mainly expressed in obviously inflam-
matory colon epithelial cells of crypts (Fig. 2 A and B). On the
other hand, TBK1 was hardly expressed in colon epithelial cells
with weak inflammation (Fig. 2 C and D).
Histological findings in the colons of DDS mice. Crypts
were diffusely absent and considerable numbers of inflammatory
cells had infiltrated colon specimens from mice in the DSS group
(Fig. 3B), whereas few crypts had disappeared and inflammatory
cell infiltration was minimal in the DSS + rebamipide group
(Fig. 3C).
Rebamipide suppressed TBK1 IRF3/7 IFN α/β signaling
pathway in DSS mice. To determine the effect of rebamipide
on the TLR-TBK1 signaling pathway in colitis, we performed
real-time RT-PCR of TBK1,  IRF3,  IRF7,  IFN-α and IFN-β on
colon specimens from DSS and from DSS + rebamipide groups.
The mRNA expression of all these genes was increased due to
inflammation in the colon of DSS mice, whereas such elevation
was suppressed in that of the DSS + rebamipide group (Fig. 4).
These results indicated that rebamipide suppresses the TBK1-
IRF3/7-IFN-α/β signaling pathway in DDS mice.
Rebamipide suppressed TLR TBK1 signaling pathway in
human colonic epithelial cells. To clarify the mechanism of
rebamipide on the TLR-TBK1 signaling pathway in colitis, we
performed both real-time RT-PCR of TBK1,  NAP1,  IRF3 and
IRF7, and Western blotting of TBK1 using human colonic
epithelial cells. Poly(I:C) (a TLR3 ligand) was added to CaCo2
colonic epithelial cells with or without rebamipide. Poly(I:C)
alone increased the mRNA expression of all of these genes in
Fig. 1. Inflammatory mucosa of UC patients over expressed TBK1 IRF3/
7 signaling pathway in human biopsy tissues. Real time RT PCR of TBK1,
NAP1, IRF3, and IRF7 confirmed the relationship between mRNA expres 
sion of these genes and ulcerative colitis in 10 patients. More TBK1,
NAP1, IRF3, and IRF7 mRNA was expressed in atypical, than in the nor 
mal mucosa of patients with UC.
Fig. 2. Immunohistochemical analysis of TBK1 in UC. TBK1 was mainly
expressed in inflammatory colon epithelial cells of crypts (A), but hardly
expressed in colon epithelial cells with weak inflammation (C). Higher
magnification of A (B). Higher magnification of C (D). (Original magnifi 
cation: A, C ×200; B, D ×400).
Fig. 3. Histological findings in the colon of DDS mice. Normal colon
mucosa of untreated mouse (A). Colon specimen from DSS mouse shows
diffuse crypt disappearance and inflammatory cell infiltration (B) indi 
cating severe colitis. Colon specimen from mouse given oral DSS and
daily rectal rebamipide, shows minimal crypt disappearance and inflam 
matory cell infiltration (C). J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 157
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the cells. However, the mRNA expression of these genes was
suppressed to control levels when both poly(I:C) and rebamipide
were added to the cells (Fig. 5). LPS, which is a ligand for TLR4,
increased the mRNA expression of all these genes in CaCo2 cells,
whereas rebamipide suppressed these LPS-induced increases to
control levels (Fig. 6). Western blotting showed that rebamipide
with either poly(I:C) or LPS suppressed TBK1 protein expression
(Fig. 7). Immunofluorescence image of TBK1 indicated that
rebamipide with LPS suppressed TBK1 protein expression
(Fig. 8). Rebamipide also suppressed the expression of TBK-1
with poly(I:C) (data not shown). These results indicated that
rebamipide suppresses the TLR3/4-TBK1 signaling pathway in
Fig. 4. Rebamipide suppressed TBK1 IRF3/7 IFN α/β signaling pathway in DSS mice. Effect of rebamipide on TLR TBK1 signaling pathway in colon
specimens from mice given oral DDS examined by real time RT PCR of TBK1, IRF3, IRF7, IFN α and IFN β. Messenger RNA expression of these genes
was increased because of colonic inflammation in DSS mice, but this increase was suppressed in DSS mice given daily rectal rebamipide.
Fig. 5. Rebamipide suppressed TLR3 TBK1 signaling pathway in human colonic epithelial cells. Effect of rebamipide on TLR3 TBK1 signaling path 
way in human colonic epithelial cells examined by both real time RT PCR of TBK1, IRF3 and IRF7 and by Western blotting of TBK1. Poly(I:C) (TLR3
ligand) was added to colonic epithelial cell line, CaCo2 with or without rebamipide. Poly(I:C) alone increased, whereas poly(I:C) plus rebamipide
suppressed the mRNA expression of all of these genes to control levels.doi: 10.3164/jcbn.10 69
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human colonic epithelial and serves as an important factor in
anti-inflammation via this pathway.
To determine the effect of rebamipide on the NF-κB signaling
pathway, we performed real-time RT-PCR of NF-κB in CaCo2
cells using the same procedure as described above. We found that
LPS increased the expression of NF-κB mRNA in CaCo2 cells
(Fig. 9), whereas LPS/poly(I:C) plus rebamipide did not suppress
the expression and the level was similar to that in the presence of
LPS/poly(I:C) (Fig. 9). These results indicated that rebamipide
does not exert anti-inflammatory effects via the NF-κB signaling
pathway.
Fig. 6. Rebamipide suppressed TLR4 TBK1 signaling pathway in human colonic epithelial cells. Lipopolysaccharide (TLR4 ligand) was added to
CaCo2 colonic epithelial cells with or without rebamipide. LPS alone increased, whereas LPS plus rebamipide suppressed mRNA expression of all of
these genes to control levels in CaCo2 cells.
Fig. 7. Effect of rebamipide on protein expression level of TBK1. West 
ern blots show that rebamipide suppressed TBK1 protein expression in
human colonic epithelial cells induced by either poly(I:C) or LPS. These
results indicate that rebamipide suppresses TLR3/4 TBK1 signaling in
these cells.
Fig. 8. Immunofluorescent image of TBK1. TBK1 expression (green)
were visualized by immunofluorescent microscopy (A, C). Nuclei were
stained blue by DAPI (B, D). TBK1 was clearly expressed in the cytoplasm
of CaCo2 cells treated with LPS (A). On the other hand, TBK1 expression
was reduced in the cytoplasm of CaCo2 cells treated with LPS and re 
bamipide (C).
Fig. 9. Effect of rebamipide on NF κB signaling pathway. Real time RT 
PCR of NF κB in human colonic epithelial cells shows that LPS and
poly(I:C) each increased NF κB gene mRNA expression in colonic epithe 
lial cells, and that adding rebamipide did not suppress either of these
increases. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 159
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Discussion
The TLRs are the best-characterized family of innate immune
receptors and they recognize conserved microbial motifs including
dsRNA and LPS. Several intestinal cell types including epithelial
cells, dendritic cells, monocyte/macrophages, granulocytes and
lymphocytes express TLRs.(25–27) Studies using mice deficient in
the MyD88 gene, which is the major signaling adaptor of the
TLR family, suggest that the predominant role of TLR/MyD88
signal transduction is to prevent intestinal inflammation.(28,29)
However, TLR/MyD88 signaling also promotes intestinal inflam-
mation,(30–32) and the inhibition of NF-κB, a major target of this
pathway, can ameliorate murine colitis.(33) On the other hand, few
studies have investigated TRIF signaling in IBD.(34) Here, we
found that the over-expression of TBK1, NAP1 and IRF3/7
activated TRIF signaling in a murine model of UC induced by
DSS. These findings suggest that TRIF signaling plays an impor-
tant role in the etiology of colitis.
Rebamipide is widely used to treat gastric ulcers in Japan(19) and
the first successful case study of rebamipide administered rectally
to a patient with IBD complicated by proctitis has recently been
published.(21) The encouraging outcome of that study indicated a
need for a prospective study to assess the safety and efficacy of
rebamipide enemas in a cohort of patients with active UC.
Rebamipide is a mucosal protective and ulcer-healing agent that
is used to treat patients with acute and chronic gastritis and to
heal gastric ulcers in Asian countries including Japan.(35–37)
Clinical and experimental data indicate that rebamipide has anti-
inflammatory properties; it scavenges free radicals,(38) and sup-
presses the production of pro-inflammatory mediators(39,40) as
well as the migration and adherence of inflammatory cells.(41,42)
Rebamipide also has mucosal protective and healing actions
through promoting prostaglandin biosynthesis,(35,43,44) mucus pro-
duction and release,(45) mucosal cell turnover,(46) and cell prolifera-
tion.(47) Because rebamipide is a radical scavenger, it has been
investigated as an alternative treatment for chronic inflammatory
diseases including colitis.(22–24,48) Anal administration of rebamipide
has protective anti-colitis effects in the colitis model induced by
tri-nitrobenzene sulfonic acid, in which colonic epithelial cells
produce low levels of antioxidants.(48) The established DSS-
induced mouse model of colitis has often been used to detect
inflammatory factors including cytokines in the colon.(49) The
therapeutic value of rebamipide has been independently confirmed
by others using models of colitis induced by acetic acid(22) or
DSS.(23,24) To our knowledge, an association between rebamipide
and TBK1-IRF3/7 signaling in colitis has not been reported. Here,
we demonstrated that rebamipide inhibited the TBK1-IRF3/7
pathway and IFN-α and IFN-β in mice with colitis induced by
DSS. We also investigated how rebamipide causes such inhibition
in colonic epithelial cells. Our data demonstrated that rebamipide
inhibited the TLRs-TBK1-IRF3/7 pathway in these cells indepen-
dently of NF-κB activation, indicating that rebamipide directly
suppresses TBK1 activation.
The type I interferons, IFN-α and IFN-β, have been evaluated
as therapy for active UC in pilot clinical trials.(50,51) IFN-β has
induced the remission of ulcerative colitis in a Japanese patient
with type C chronic hepatitis.(52) Our findings seem to contradict
these reports. Whether IFN-β had a positive or a negative effect
upon the mucosa was unclear. However, a systematic review
concluded that type I IFNs cannot be recommended as treatment
for active UC.(53) The contradictory effect of IFN-β might be dose-
related.
In conclusion, the TLR-TBK1-IRF3/7 pathway might be one
etiology of IBD and rebamipide directly thwarts this pathway.
However, further studies are required to clarify the mechanism of
action.
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